RE: RNSs The Architecture Expands29 Oct 2025 08:18
Good Morning : Missed this bit - relative to commercials - get the message out there
--------------
Courtesy AL X tweet
"
Al
@Allie_aa_
·
14h
Part2
•The Meta Shift
The rerate starts to brew the moment the data and funding structure enter the models watched by Big Pharma and institutional algorithms.
First it was GlobeNewswire, then Yahoo Finance, Morningstar, Apple Stocks, FT, and Proactive.
To the untrained eye, it looks like coverage but it’s not. It’s indexing.
Once an RNS hits those pipes, it becomes code; structured, machine readable, fund searchable, model grade input.
That information flows into sentiment engines, quant dashboards, and algorithmic filters that tell capital what’s worth watching.
Now the narrative has both sides of the equation:
Scientific validation (Boston data).
Financial stability (convertible restructuring + equity raise).
What this means:
When outlets like Yahoo Finance, Morningstar, FT, Proactive and others combine R&D breakthroughs with capital structure improvements, they go beyond headlines; they mark the point where institutional recognition starts to take shape reflecting both visibility and investment utility.
The science gives it credibility; the funding gives it runway.
Together, they form a narrative that investors and algorithms recognise as a platform emerging from discovery into deployment. Keywords (FAPactivated, dual payload, resistance, synergy, extended runway) gets parsed, scored, and mapped into oncology innovation models.
Once tagged in the right clusters (Oncology Innovation, Platform Therapeutics, NextGen Delivery), #AVCT starts appearing beside Moderna, Alnylam, Seagen in institutional screens.
That visibility becomes value.
Because the rerate starts forming the moment the machines begin rewriting their assumptions.. long before the market catches up."
Gmcc
Sign In
Follow the stocks
